Clinical Trials Browser

Active not recruiting × belzutifan × 30 days × Clear all

NCT04626479 2026-05-18

MK-3475-03A

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05239728 2026-05-15

MK-6482-022

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase 3 Active not recruiting

755 enrolled 28 charts 1 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04626518 2026-05-06

KEYMAKER-U03

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04736706 2026-05-06

MK-6482-012

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell